Headache and fever are common after oral administration of rotavirus vaccine, and serious adverse events are generally rare. The full name of the vaccine is also known as oral live attenuated pentavalent reassortant rotavirus vaccine, which is intended for use in infants between 6 and 32 weeks of age to prevent rotavirus gastroenteritis in infants and children caused by serotypes G1, G2, G3, G4, and G9. Since the vaccine is live attenuated, it can only be taken orally but not injected. For infants, there are often some adverse reactions after taking the vaccine, including headache, fever, occasional upper respiratory tract infections, cough, nasal congestion, otitis media, as well as gastrointestinal symptoms such as abdominal pain, blood in the stools, fecal abnormalities, gastric upset, etc. In more serious cases, viral gastroenteritis, respiratory tract infections, malaise, dehydration and other symptoms may occur. Symptoms. According to the relevant product insert, the chance of adverse reactions among all subjects in the phase III clinical trial was small, and no serious adverse events related to the vaccine have occurred. However, the vaccine is not suitable for all infants. It is strictly prohibited for those who have hypersensitivity reactions to any component of the vaccine, those with severe combined immunodeficiency diseases, and those with a previous history of intussusception. It is recommended that a physician be consulted before oral administration of the pentavalent vaccine, and the vaccine may be administered if there are no clear contraindications.